OKYO Pharma Ltd ADR - Asset Resilience Ratio

Latest as of March 2023: 84.69%

OKYO Pharma Ltd ADR (OKYO) has an Asset Resilience Ratio of 84.69% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check OKYO Pharma Ltd ADR (OKYO) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$4.41 Million
Cash + Short-term Investments

Total Assets

$5.20 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2009–2017)

This chart shows how OKYO Pharma Ltd ADR's Asset Resilience Ratio has changed over time. See OKYO net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down OKYO Pharma Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of OKYO Pharma Ltd ADR.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $4.41 Million 84.69%
Total Liquid Assets $4.41 Million 84.69%

Asset Resilience Insights

  • Very High Liquidity: OKYO Pharma Ltd ADR maintains exceptional liquid asset reserves at 84.69% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

OKYO Pharma Ltd ADR Industry Peers by Asset Resilience Ratio

Compare OKYO Pharma Ltd ADR's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for OKYO Pharma Ltd ADR (2009–2017)

The table below shows the annual Asset Resilience Ratio data for OKYO Pharma Ltd ADR.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2017-03-31 60.74% $16.86 Million $27.76 Million +9.96pp
2010-03-31 50.77% $27.49 Million $54.13 Million -15.22pp
2009-03-31 65.99% $25.25 Million $38.27 Million --
pp = percentage points

About OKYO Pharma Ltd ADR

NASDAQ:OKYO USA Biotechnology
Market Cap
$59.80 Million
Market Cap Rank
#21275 Global
#4709 in USA
Share Price
$1.59
Change (1 day)
-1.85%
52-Week Range
$1.34 - $3.27
All Time High
$3.74
About

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more